CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.

More Content by Providence News Team
Previous Article
The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed
The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed

The new center will enhance our care for the 5,000 oncology patients we see every year – and the hundreds ...

Next Article
Nobel Prize Honors Immunotherapy Researchers; Work Included Clinical Trials Led by Providence Dr. Walter Urba
Nobel Prize Honors Immunotherapy Researchers; Work Included Clinical Trials Led by Providence Dr. Walter Urba

The Nobel Prize in Medicine has been awarded to two cancer immunotherapy researchers, work included clinica...